Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Inclusion criteria

• Female.
• Age 20-65 years.
• Invasive carcinoma confirmed by core biopsy.
• Newly diagnosed breast cancer patients, without adjuvant therapy.
• Imaging findings showed a single breast tumor with a maximum diameter of 3 cm, no distant metastasis, and no invasion of the skin and chest wall.
• Systematic ultrasound is able to visualize lesions.
• Surgical treatment was planned.
• The functional level of major organs must meet the following requirements:

• blood routine: neutrophil (ANC) ≥ 1.5 × 109/L; platelet count (PLT) ≥ 90 × 109/L; hemoglobin (Hb) ≥ 90 g/L;
• blood biochemistry: total bilirubin (TBIL) ≤ upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN;
• coagulation: international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
• Heart: left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiography (ECHO) or multigated acquisition (MUGA).
• Thyroid function: thyroid stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be investigated, and normal T3 and T4 levels can be included.
• Urinalysis: urine protein < 2 +, if urine protein ≥ 2 +, 24-hour urine protein quantification must show protein ≤ 1 g.
• Voluntarily participate in this study, sign informed consent, have good compliance and are willing to cooperate with follow-up.

Exclusion criteria

• Tumor involving skin, ulceration, inflammatory breast cancer patients
• Fatty breast cancer.
• Tumors on the deep surface of areolar region
• KPS score < 70, or ECOG score > 2
• Patients with a history of concomitant collagen connective tissue disease, or any active autoimmune disease or autoimmune disease.
• Prior radiotherapy or prior use of investigational drugs or other immunosuppressive agents
• Heart, brain, lung, kidney and other vital organ failure, liver and kidney dysfunction;
• Uncorrectable severe coagulopathy
• Patient is pregnant or lactating
• Poor glycemic control in diabetes
• Patients with foreign body implantation around the tumor
• Patients with severe scars on the skin of the treatment area (protruding from the skin surface, width ≥ 1 cm)
• History of chronic immunosuppression, prior immunotherapy, recent vaccination (< 4 weeks)
• Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B indicates antigen positive and HBV DNA ≥ 500 IU/ml), hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower limit of detection of the analytical method).
• Concurrent medical conditions that, in the judgment of the investigator, would jeopardize the subject's safety, could confound the study results, or affect the subject's completion of this study.